Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies

• Main Authors: Andrea Chiricozzi, Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni
• Format: Article
• Language: English
• Published: MDPI AG 2020-12-01
• Series: Vaccines
• Subjects: psoriasis; vaccination; vaccine; biologics; methotrexate; cyclosporine
• Online Access: https://www.mdpi.com/2076-393X/8/4/769

Psoriasis is a chronic inflammatory skin disease usually treated with immunomodulatory/immunosuppressive agents. The use of these agents has been associated with an increased susceptibility to infections. Vaccination might represent a critical aspect in the management of patients with psoriasis treated with immunomodulatory/immunosuppressive therapies. This narrative review aimed to provide an overview on the immune response to vaccines in subjects treated with systemic agents used to treat patients with moderate to severe psoriasis. Publications appearing in PubMed, Scopus, and ISI–Web of Knowledge database were selected using Medical Subject Headings key terms. Overall, published data confirmed that vaccination with attenuated live vaccines during therapy with immunomodulatory/immunosuppressive therapies should be avoided. For nonlive vaccines, a more favorable safety profile of biologic agents compared to conventional systemic agents is described as the humoral response to vaccines is in general well-preserved. Treatment with cyclosporine and methotrexate is associated with lower antibody titers to vaccines, and thus these agents are better discontinued during vaccination. In contrast, treatment with biological agents is not associated with lower antibody response and can thus be continued safely.